10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 1,101–1,169 of 1,169
Identifying barriers and facilitators to self care in young adults with type 2 diabetes
Wong, S. K. W., Soon, W., Griva, K., & Smith, H. E. (2024) · Diabetic Medicine · doi:10.1111/dme.15229 · Cited by 33
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Relationship between Sleep Disorders and the Risk for Developing Type 2 Diabetes Mellitus
Ioja, S., Weir, I. D., & Rennert, N. J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2573 · Cited by 32
Lee, D. Y., Park, J., Choi, D., Ahn, H.-Y., Park, S.-W., & Park, C.-Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-22034-0 · Cited by 31
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…microvascular (e.g. retinopathy, nephropathy) and macrovascular (e.g. CAD, stroke) complications in both type 1 diabetes mellitus (T1DM) and T2DM (Holman et al., 2008), although several similar large-scale trials have reported limited benefits (Action to Control Cardiovascular Risk in Diabetes…”
BackgroundChu, P. Y., Hackstadt, A. J., Chipman, J., Griffin, M. R., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T., & Roumie, C. L. (2020) · Diabetes Care · doi:10.2337/dc19-2391 · Cited by 31
“Number medications* 7 (5, 11) 7 (4, 10) 7 (4, 10) 7 (4, 10) 0.”
Whitehead, L. C., Crowe, M. T., Carter, J. D., Maskill, V. R., Carlyle, D., Bugge, C., & Frampton, C. M. A. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12594 · Cited by 31
Barriers and enablers to make lifestyle changes among type 2 diabetes patients a review
Mohamed Nor, N., Mohd Shukri, N. A., Mohd Yassin, N. Q. A., Sidek, S., & Azahari, N. (2019) · Sains Malaysiana · doi:10.17576/jsm-2019-4807-18 · Cited by 30
Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub3 · Cited by 30
Point-of-care HbA1c in clinical practice: caveats and considerations for optimal use
Sacks, D. B., Kirkman, M. S., & Little, R. R. (2024) · Diabetes Care · doi:10.2337/dci23-0040 · Cited by 29
How are qualitative methods used in diabetes research? A 30-year systematic review
Hennink, M. M., Kaiser, B. N., Sekar, S., Griswold, E. P., & Ali, M. K. (2017) · Global Public Health · doi:10.1080/17441692.2015.1120337 · Cited by 28
Changes in Albumin Excretion in the Diabetes Prevention Program
Diabetes Prevention Program Research Group (2009) · Diabetes Care · doi:10.2337/dc08-1400 · Cited by 26
Carlsson, A. C., Nixon Andreasson, A., & Wändell, P. E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.03.005 · Cited by 26
Kuramitsu, S., Yokoi, H., Domei, T., Nomura, A., Watanabe, H., Yamaji, K., Soga, Y., Arita, T., Kondo, K., Shirai, S., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-74 · Cited by 26
“Furthermore, the benefits of early intensive therapy to control blood glucose levels in patients with newly diagnosed DM were sustained for up to 10 years after cessation of intensive therapy [34].”
Vluggen, S., Candel, M., Hoving, C., Schaper, N. C., & de Vries, H. (2021) · Journal of Medical Internet Research · doi:10.2196/18524 · Cited by 26
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
McKenzie, A. L., Athinarayanan, S. J., Van Tieghem, M. R., Volk, B. M., Roberts, C. G. P., Adams, R. N., Volek, J. S., Phinney, S. D., & Hallberg, S. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111898 · Cited by 25
Early Insulin Use in Type 2 Diabetes
Chiasson, J.-L. (2009) · Diabetes Care · doi:10.2337/dc09-s321 · Cited by 24
García de la Torre, N., Durán, A., del Valle, L., Fuentes, M., Barca, I., Martín, P., Montañez, C., Perez-Ferre, N., Abad, R., Sanz, F., et al. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0467-9 · Cited by 24
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Approaches to risk assessment among older patients with diabetes
Pilla, S. J., Schoenborn, N. L., Maruthur, N. M., & Huang, E. S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1172-z · Cited by 24
Kim, S. K., Kim, H. J., Kim, T., Hur, K. Y., Kim, S. W., Lee, M.-K., Min, Y.-K., Kim, K.-W., Chung, J. H., & Kim, J. H. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.6.449 · Cited by 23
Kalain, A., & Omole, O. B. (2020) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v12i1.2163 · Cited by 22
Cardiovascular risk reduction following metabolic and bariatric surgery.
Albaugh, V. L., Kindel, T. L., Nissen, S. E., & Aminian, A. (2021) · Surgical Clinics of North America · doi:10.1016/j.suc.2020.12.012 · Cited by 21
Ketoconazole enantiomer for the treatment of diabetes mellitus
Arakaki, R., & Welles, B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903381411 · Cited by 21
“The 10-year follow-up of the UKPDS cohort showed significant reductions in microvascular and macrovascular complications with intensive treatment with sulfonylureas, metformin, or insulin [2].”
BackgroundGarcia-Alcala, H., Soto Vega, E., Genestier Tamborero, C. N., Salinas Palma, J. L., & Hirales Tamez, O. (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s35545 · Cited by 21
“However, results from different long-term well designed trials have been modest in terms of prevention of microvascular and macrovascular complications.(4) Prevention and/or early diagnosis of diabetes have now emerged as more promising strategies to reduce both the prevalence of the disease and development of its com…”
BackgroundStandl, E., Erbach, M., & Schnell, O. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2355 · Cited by 20
“[29] and for type 2 diabetes in the ten year follow-up study of the randomized UKPD Study [30], though there may be limiting factors of aiming at near-normal glyce-”
BackgroundHeller, S. R., Pratley, R. E., Sinclair, A., Festa, A., Kiljański, J., Brusko, C. S., Duan, R., & Heine, R. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13051 · Cited by 18
Ren, Y., Ren, Q., Lu, J., Guo, X., Huo, X., Ji, L., & Yang, X. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2960 · Cited by 18
“Increased levels of FFA flux to the liver and increase synthesis of hepaticTG and apolipoprotein C‐III in the liver and secretion of TG‐rich very‐low‐density lipoprotein (VLDL) containing apolipoprotein C‐III, leading to elevated levels of TG in the plasma.25 Triglyceride‐rich VLDL is associated with increased proinfl…”
BackgroundInfluentialDiabetische Neuropathie und diabetischer Fuß (Update 2019)
Lechleitner, M., Abrahamian, H., Francesconi, C., Kofler, M., Sturm, W., & Köhler, G. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1487-4 · Cited by 18
Maegawa, H., Ishigaki, Y., Langer, J., Saotome‐Nakamura, A., Andersen, M., & the Japan Diabetes Clinical Data Management (JDDM) Study Group (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13352 · Cited by 18
Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
(2015) · Europe PMC (PubMed Central) · Cited by 18
Kan, K., Zhu, W., Lu, F., Shen, Y., Gao, F., Mo, Y., He, X., Bao, Y., Zhou, J., & Jia, W. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0275 · Cited by 16
Bajaj, H. S., Welch, M., Shah, P., Luna, E., Jaouimaa, F.-Z., Liu, B., Liu, R., Chen, Y., Patel, H., & Bartee, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00967-0 · Cited by 23
Mannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16
“26 The SPREAD-DIMCAD 27 Overall, available evidence is insufficient to show a significant reduction in the incidence of MACE in patients without ASCVD with any class of drugs for diabetes.”
MethodManagement of severe insulin resistance in patients with type 1 diabetes
Schechter, R., & Reutrakul, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0641-2 · Cited by 15
Glycaemic management of type 2 diabetes
Srinivasan, B. T., & Davies, M. (2019) · Medicine · doi:10.1016/j.mpmed.2018.10.009 · Cited by 14
Li, M., Liu, S., Yu, B., Li, N., Lyu, A., Yang, H., He, H., Zhang, N., Ma, J., Sun, M., et al. (2025) · Journal of Medical Internet Research · doi:10.2196/63209 · Cited by 12
“Controlling glucose levels and body weight within the normal range can effectively reduce the complications of patients with diabetes [10].”
Uptake and use of a diabetes management program with a mobile glucometer
Garabedian, L. F., Ross-Degnan, D., LeCates, R. F., & Wharam, J. F. (2019) · Primary Care Diabetes · doi:10.1016/j.pcd.2019.03.010 · Cited by 13
Dambha-Miller, H., Hounkpatin, H. O., Stuart, B., Farmer, A., & Griffin, S. (2023) · PLOS ONE · doi:10.1371/journal.pone.0290791 · Cited by 13
“Observational studies consistently demonstrate a positive association between glycaemia and CVD [5], whereas evaluations of interventions to lower glucose report heterogeneous findings [6–8].”
Aroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
“The importance of good glycemic control has been well established and has been shown to reduce the risk of long-term diabetes complications such as retinopathy and nephropathy (3,4).”
BackgroundPedersen, E., Lange, K., & Clifton, P. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.135343 · Cited by 13
Tschöpe, D., Bramlage, P., Schneider, S., & Gitt, A. K. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115610470 · Cited by 12
do Rosário Pinto, M., Parreira, P. M. D. S., Basto, M. L., & dos Santos Mendes Mónico, L. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0222-2 · Cited by 12
“In addition, evidence has highlighted the importance of developing and implementing interventions that can reduce this burden, by using intensive strategies to control blood glucose levels [9, 10], pointing lifestyle correction as one of the most important aims for people with type 2 diabetes [4, 11, 12].”
BackgroundLiu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12
Medical Treatment of Peripheral Artery Disease
Gornik, H. L., & Creager, M. A. (2013) · Vascular Medicine: A Companion to Braunwald's Heart Disease · doi:10.1016/b978-1-4377-2930-6.00019-7 · Cited by 12
Nemlekar, P. M., Hannah, K. L., & Norman, G. J. (2023) · Clinical Diabetes · doi:10.2337/cd22-0080 · Cited by 10
Agvall, B., Jonasson, J. M., Galozy, A., & Halling, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02211-4 · Cited by 10
“This aligns with the definition of CVD events as macrovascular [26].”
BackgroundMethodbrief history of the UK Prospective Diabetes Study: RURY R HOLMAN, FOR THE UKPDS GROUP
Holman, R. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.359 · Cited by 10
Self-citationAli, M. K., Singh, K., Kondal, D., Devarajan, R., Patel, S. A., Menon, V. U., Varthakavi, P. K., Vishwanathan, V., Dharmalingam, M., Bantwal, G., et al. (2024) · PLOS Medicine · doi:10.1371/journal.pmed.1004335 · Cited by 10
Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J. F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.04.030 · Cited by 9
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
Romera, I., Gomis, R., Crowe, S., de Pablos-Velasco, P., Aranda, U., García, A., Kis, S. G., & Naderali, E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.016 · Cited by 9
Park, L., & Wexler, D. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328332dfaa · Cited by 9
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.016 · Cited by 9
Gregg, E. W., & Moin, T. (2021) · JAMA · doi:10.1001/jama.2021.12559 · Cited by 9
Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
Dadwani, R. S., Wan, W., Skandari, M. R., & Huang, E. S. (2023) · MDM Policy & Practice · doi:10.1177/23814683231187566 · Cited by 8
“The rate of medication use in the original UKPDS cohort is previously reported.(37)”
MethodSacks, D. B. (2012) · Tietz Textbook of Clinical Chemistry and Molecular Diagnostics · doi:10.1016/b978-1-4160-6164-9.00046-9 · Cited by 7
Thalange, N., Gundgaard, J., Parekh, W., & Tutkunkardas, D. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000664 · Cited by 7
“7 Accordingly, a key goal of insulin therapy is to maintain optimal blood glucose levels and prevent the development of these acute diabetes-related complications.(8) 9 New-generation long-acting insulin analogs with improved pharmacokinetic and pharmacodynamic profiles have been developed, and these have the potentia…”
BackgroundA Regulatory Pathway for Medicines That Target Aging
Fleming, G. A., Zhao, J. H., Seoh, T. C., & Barzilai, N. (2019) · Public Policy & Aging Report · doi:10.1093/ppar/prz018 · Cited by 7
Yang, W., Ersoy, C., Wang, G., Ye, S., Liu, J., Miao, H., Asirvatham, A., Werther, S., Kadu, P., & Chow, F. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.023 · Cited by 6
Pi, L., He, B., Fei, D., Shi, X., & Zhou, Z. (2024) · BMC Primary Care · doi:10.1186/s12875-024-02600-4 · Cited by 6
Li, Z., Luo, D., & Li, Z. (2025) · Endocrine Connections · doi:10.1530/ec-24-0576 · Cited by 6
Llinás-Castro, R., Alvis-Estrada, L., & Durán-Lengua, M. (2018) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v66n4.58933 · Cited by 5
“(26) In addition, it has been evidenced that early and effective insulin intervention is important because inhibiting glucotoxicity and decreasing the onset of complications may be beneficial to preserve functional beta-cell mass.”
BackgroundClinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i
Lanzinger, S., Schmid, S. M., Welp, R., Zimmermann, A., Fasching, P., Wagner, S., & Holl, R. W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.011 · Cited by 4
Gaetani, M. L., Pinto, I. C., Li, M., O’Connor, P., Giorgi-Coll, S., Tyreman, M., Rumary, K. L., Schouten, J. A., Davis, P., & Dixon, A. M. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2023.12.008 · Cited by 3
Balkau, B., Halimi, S., Blickle, J.-F., Vergès, B., Avignon, A., Attali, C., Chartier, I., & Amelineau, E. (2016) · Annales d'Endocrinologie · doi:10.1016/j.ando.2016.03.001 · Cited by 3
DreamTel; diabetes risk evaluation and management tele-monitoring study protocol
Tobe, S. W., Wentworth, J., Ironstand, L., Hartman, S., Hoppe, J., Whiting, J., Kennedy, J., McAllister, C., Kiss, A., Perkins, N., et al. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-13 · Cited by 2
“Control of blood glucose levels prevents new microvascular disease and has recently been shown to have a legacy effect and is a central focus of diabetes management programs[3], in addition to the significant health benefits of blood pressure and lipid control.”
Goh, J. S. R., Sim, L. X., Seetho, I. W., Kao, S. L., Chin, R. T., Khoo, C. M., Lim, A. Y. L., & Eng, P. C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903159
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.